Cell therapy
| Cell Source | Indication | Non-clinicalIND | Clinical ProgressBLA | FDA Approval | |||
|---|---|---|---|---|---|---|---|
| Research Stage | Non-clinical Trial | Phase I | Phase II | Phase III | |||
Cell Source: Cord Blood REGENECYTE® |
|||||||
| REGENECYTE® Cord Blood
|
About 80 Hematologic Diseases |
||||||
| Long COVID | |||||||
| Acute Stroke | |||||||
| Cerebral Palsy | |||||||
| REGENECYTE® is a US FDA-approved allogeneic cord blood cell biologic that can be used to treat over 80 indications, including 17 types of cancer (such as leukemia, multiple myeloma, and neuroblastoma), 20 blood disorders (such as beta-thalassemia, congenital aplastic anemia, and myelodysplastic syndrome), 26 immune-related disorders (such as severe combined immunodeficiency, SCID), and 17 metabolic disorders (such as mucopolysaccharidosis and adrenoleukodystrophy). To date, REGENECYTE® has been successfully used in the treatment of over 2,300 patients worldwide. In addition to its approved indications, REGENECYTE® is currently undergoing clinical trials for Long COVID syndrome, acute ischemic stroke, and cerebral palsy, continuing to expand its potential therapeutic applications. 80 Indications Treatable by Cord Blood Transplant |
|||||||
Cell Source: Cord Blood Immune Cells |
|||||||
| Cord Blood Immune Cells | Cancer | ||||||